Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mass campaigns with oral poliovirus vaccine (OPV) have brought the world close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself be withdrawn to prevent outbreaks of vaccine-derived poliovirus (VDPV). Synchronized global withdrawal of OPV began with serotype 2 OPV (OPV2) in April 2016, which presented the first test of the feasibility of eradicating all polioviruses. METHODS: We analyzed global surveillance data on the detection of serotype 2 Sabin vaccine (Sabin-2) poliovirus and serotype 2 vaccine-derived poliovirus (VDPV2, defined as vaccine strains that are at least 0.6% divergent from Sabin-2 poliovirus in the viral protein 1 genomic region) in stool samples from 495,035 children with acute flaccid paralysis in 118 countries and in 8528 sewage samples from four countries at high risk for transmission; the samples were collected from January 1, 2013, through July 11, 2018. We used Bayesian spatiotemporal smoothing and logistic regression to identify and map risk factors for persistent detection of Sabin-2 poliovirus and VDPV2. RESULTS: The prevalence of Sabin-2 poliovirus in stool samples declined from 3.9% (95% confidence interval [CI], 3.5 to 4.3) at the time of OPV2 withdrawal to 0.2% (95% CI, 0.1 to 2.7) at 2 months after withdrawal, and the detection rate in sewage samples declined from 71.0% (95% CI, 61.0 to 80.0) to 13.0% (95% CI, 8.0 to 20.0) during the same period. However, 12 months after OPV2 withdrawal, Sabin-2 poliovirus continued to be detected in stool samples (<0.1%; 95% CI, <0.1 to 0.1) and sewage samples (8.0%; 95% CI, 5.0 to 13.0) because of the use of OPV2 in response to VDPV2 outbreaks. Nine outbreaks were reported after OPV2 withdrawal and were associated with low coverage of routine immunization (odds ratio, 1.64 [95% CI, 1.14 to 2.54] per 10% absolute decrease) and low levels of population immunity (odds ratio, 2.60 [95% CI, 1.35 to 5.59] per 10% absolute decrease) within affected countries. CONCLUSIONS: High population immunity has facilitated the decline in the prevalence of Sabin-2 poliovirus after OPV2 withdrawal and restricted the circulation of VDPV2 to areas known to be at high risk for transmission. The prevention of VDPV2 outbreaks in these known areas before the accumulation of substantial cohorts of children susceptible to type 2 poliovirus remains a high priority. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationGlobal polio eradication initiative
Koenig‐Archibugi, M. (2011) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 523
Environmental surveillance for polioviruses in the Global Polio Eradication Initiative.
Asghar, H., Diop, O. M., Weldegebriel, G., Malik, F., Shetty, S., El Bassioni, L., Akande, A. O., Al Maamoun, E., Zaidi, S., Adeniji, A. J., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu384 · Cited by 427 · cited 1×
“for the presence of polioviruses, is currently performed in over 30 countries to supplement AFP surveillance.(5,6) Here we analyse ES data from four high-risk countries in the Eastern-Mediterranean”
MethodSelf-citationVaccine Policy Changes and Epidemiology of Poliomyelitis in the United States
Alexander, L. N. (2004) · JAMA · doi:10.1001/jama.292.14.1696 · Cited by 203
Hampton, L. M., Farrell, M., Ramirez-Gonzalez, A., Menning, L., Shendale, S., Lewis, I., Rubin, J., Garon, J., Harris, J., Hyde, T., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6535a3 · Cited by 193
(2012) · PubMed · Cited by 168
The Evolutionary Pathway to Virulence of an RNA Virus
Stern, A., Yeh, M. T., Zinger, T., Smith, M., Wright, C., Ling, G., Nielsen, R., Macadam, A., & Andino, R. (2017) · Cell · doi:10.1016/j.cell.2017.03.013 · Cited by 127
Apparent global interruption of wild poliovirus type 2 transmission.
(2001) · PubMed · Cited by 107
Is Polio Eradication Realistic?
Arita, I., Nakane, M., & Fenner, F. (2006) · Science · doi:10.1126/science.1124959 · Cited by 93
Modeling the Dynamics of Oral Poliovirus Vaccine Cessation
Thompson, K. M., & Tebbens, R. J. D. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit845 · Cited by 84
Research works printed but not linked: 2
- Polio laboratory manual 4th edition. Geneva: World Health Organization 2004 (http://polioeradication.org/wp-content/uploads/2017/05/Polio_Lab_Manual04.pdf).
- Watanabe S. Asymptomatic equivalence of Bayes cross validation and widely applicable information criterion in singular learning theory. J Mach Learn Res 2010;11:3571-3594.
Cited by
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citationMacklin, G. R., O’Reilly, K. M., Grassly, N. C., Edmunds, W. J., Mach, O., Santhana Gopala Krishnan, R., Voorman, A., Vertefeuille, J. F., Abdelwahab, J., Gumede, N., et al. (2020) · Science · doi:10.1126/science.aba1238 · Cited by 141
Self-citationDevelopment of a new oral poliovirus vaccine for the eradication end game using codon deoptimization
Konopka-Anstadt, J. L., Campagnoli, R., Vincent, A., Shaw, J., Wei, L., Wynn, N. T., Smithee, S. E., Bujaki, E., Te Yeh, M., Laassri, M., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0176-7 · Cited by 96
Rosenkranz, S., Lang, I. M., Blindt, R., Bonderman, D., Bruch, L., Diller, G., Felgendreher, R., Gerges, C., Hohenforst‐Schmidt, W., Holt, S., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.080 · Cited by 81
Ivanova, O. E., Yarmolskaya, M. S., Eremeeva, T. P., Gm, B., Baykova, O. Y., Akhmadishina, L. V., Krasota, A. Y., Kozlovskaya, L. I., & Lukashev, A. N. (2019) · Viruses · doi:10.3390/v11050424 · Cited by 64
“It has been shown that even in absence of OPV, a substantial fraction of sewage samples (up to 8%) can contain Sabin 2 strains [28].”
BackgroundReview of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
Thompson, K. M., & Kalkowska, D. A. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1791093 · Cited by 68
“Following the search process shown in Figure 1, the systematic literature review and addition of other studies by the three GPEI-supported modeling groups led to the extraction of information from 176 included studies [1-4, 8-179].”
BackgroundMethodInfluentialCooper, L., Bandyopadhyay, A. S., Gumede, N., Mach, O., Mkanda, P., Ndoutabé, M., Okiror, S. O., Ramirez-Gonzalez, A., Touray, K., Wanyoike, S., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00453-9 · Cited by 60
Self-citationGerhardt, F., Dumitrescu, D., Gärtner, C., Beccard, R., Viethen, T., Kramer, T., Baldus, S. E., Hellmich, M., Schönaü, E., & Rosenkranz, S. (2017) · Heart · doi:10.1136/heartjnl-2016-309852 · Cited by 52
Kalkowska, D. A., Pallansch, M. A., Wilkinson, A. L., Bandyopadhyay, A. S., Konopka‐Anstadt, J. L., Burns, C. C., Oberste, M. S., Wassilak, S. G. F., Badizadegan, K., & Thompson, K. M. (2020) · Risk Analysis · doi:10.1111/risa.13622 · Cited by 48
“Transmission of cVDPV2s continues to date in increasing numbers of geographies (Blake et al., 2018; Kalkowska, Pallansch et al., 2020; Macklin et al., 2020), some of which appear to be associated with use of mOPV2 for outbreak response leading to the emergence of new cVDPV2s.”
BackgroundSelf-citationAssessing the sensitivity of the polio environmental surveillance system
Kroiss, S. J., Ahmadzai, M., Ahmed, J., Alam, M. M., Chabot‐Couture, G., Famulare, M., Mahamud, A. S., McCarthy, K. A., Mercer, L. D., Salman, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208336 · Cited by 46
“Blake et al [22] studied rates of Sabin type 2 detection in environmental surveillance sites related to OPV2 use in vaccination campaigns for the purposes of evaluating the global switch from trivalent OPV to bivalent OPV in 2016.”
BackgroundPoliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus
Quarleri, J. F. (2022) · GeroScience · doi:10.1007/s11357-022-00672-7 · Cited by 46
Kalkowska, D. A., Pallansch, M. A., Cochi, S. L., Kovacs, S., Wassilak, S. G. F., & Thompson, K. M. (2020) · Risk Analysis · doi:10.1111/risa.13555 · Cited by 37
“…but also highlighted some areas with limited programmatic performance and raised the potential need to restart OPV2 use beyond only outbreak response use (e.g., in routine immunization) (Blake et al., 2018; Duintjer Tebbens & Thompson, 2018; Kroiss et al., 2017; Thompson & Duintjer Tebbens, 2017).”
BackgroundHill, M., Bandyopadhyay, A. S., & Pollard, A. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01582-3 · Cited by 33
Self-citationEradicating Polio: How the World’s Pediatricians Can Help Stop This Crippling Illness Forever
Orenstein, W. A. (2014) · PEDIATRICS · doi:10.1542/peds.2014-3163 · Cited by 33
Mohammed, S., Vijayvergiya, R., Malhotra, S., & Rohit, M. K. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.07.007 · Cited by 32
The role of genetic sequencing and analysis in the polio eradication programme
Jorgensen, D., Pons-Salort, M., Shaw, A. G., & Grassly, N. C. (2020) · Virus Evolution · doi:10.1093/ve/veaa040 · Cited by 31
Self-citationValesano, A. L., Taniuchi, M., Fitzsimmons, W. J., Islam, M. O., Ahmed, T., Zaman, K., Haque, R., Wong, W., Famulare, M., & Lauring, A. S. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.10.011 · Cited by 31
Chen, P., Liu, Y. Z., Wang, H., Liu, G., Lin, X., Zhang, W., Ji, F., Xu, Q., Tao, Z., & Xu, A. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.00702-20 · Cited by 28
“In rare instances, OPV can cause VAPP, but more seriously, this live-attenuated vaccine will lead to outbreaks of cVDPV. Researchers have also documented that more countries have suffered a polio outbreak due to a cVDPV (especially cVDPV2) than due to a WPV (2, 4, 5), especially since the global cVDPV cases have excee…”
BackgroundInfluentialWahid, R., Mercer, L. D., Macadam, A. J., Carlyle, S., Stephens, L., Martín, J. E.-S., Chumakov, K., Laassri, M., Petrovskaya, S. N., Smits, S. L., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00355-y · Cited by 29
Self-citationSpherical nucleic acids-based nanoplatforms for tumor precision medicine and immunotherapy
Liu, S., Yu, C., & Wei, H. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100750 · Cited by 26
Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020
Macklin, G., Goel, A. K., Mach, O., Tallis, G. F., Ahmed, J., O’Reilly, K. M., Grassly, N. C., & Diop, O. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.008 · Cited by 22
Self-citationWahid, R., Mercer, L. D., León, T. D., DeAntonio, R., Sáez‐Llorens, X., Macadam, A. J., Chumakov, K., Strating, J. R. P. M., Koel, B. F., Konopka‐Anstadt, J. L., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00254-3 · Cited by 22
Self-citationModeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria
Kalkowska, D. A., Franka, R., Higgins, J., Kovacs, S., Forbi, J. C., Wassilak, S. G. F., Pallansch, M. A., & Thompson, K. M. (2020) · Risk Analysis · doi:10.1111/risa.13485 · Cited by 16
“…cVDPV2 in Sokoto (a state in northwest Nigeria), which signaled the failure of efforts by Nigeria to perform effective tOPV campaigns prior to OPV2 cessation to sufficiently boost population immunity to transmission in all communities (Blake et al., 2018; Duintjer Tebbens & Thompson, 2017).”
BackgroundDevaux, C. A., Pontarotti, P., Levasseur, A., Colson, P., & Raoult, D. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1284337 · Cited by 16
Gray, E. J., Cooper, L., Bandyopadhyay, A. S., Blake, I. M., & Grassly, N. C. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad004 · Cited by 13
“Thus, low levels of preexisting OPV-induced serotype-2 immunity in a population are correlated with persistent detection of Sabin viruses following an SIA [7], giving more opportunity for reversion to a VDPV2.”
BackgroundInfluentialSelf-citationBelgasmi, H., Miles, S. J., Sayyad, L., Wong, K., Harrington, C., Gerloff, N. A., Coulliette-Salmond, A. D., Guntapong, R., Tacharoenmuang, R., Ayutthaya, A. I. N., et al. (2022) · Frontiers in Environmental Science · doi:10.3389/fenvs.2022.914387 · Cited by 13
“The reported cVDPV cases in 2020 and 2021 were 1,113 and 628, respectively, from 33 countries, indicating that the cVDPV cases have exceeded the number of WPV globally (Organization, 2019).”
MethodInfluentialSun, Y., Keskinocak, P., Steimle, L. N., Kovacs, S. D., & Wassilak, S. G. F. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100476 · Cited by 12
“…and the related challenges in these zones [23], including the historically dominant use of vaccines containing no type 2 viruses [32,33], low-coverage EI (which comprises of two IPV doses against type 2 as of July 2021) and SIAs [10,14,23,32], insurgency [12,34], and vaccine hesitancy [35].”
BackgroundTian, X., Han, Z., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Virology Journal · doi:10.1186/s12985-021-01590-4 · Cited by 11
Cologne consensus conference on pulmonary hypertension – Update 2018
Rosenkranz, S., Ghofrani, H. A., Grünig, E., Klose, H. F. E., Olschewski, H., & Hoeper, M. M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.064 · Cited by 11
The Husavirus Posa-Like Viruses in China, and a New Group of Picornavirales
Han, Z., Xiao, J., Song, Y., Hong, M., Dai, G., Lu, H., Zhang, M., Liang, Y., Yan, D., Zhu, S., et al. (2020) · Viruses · doi:10.3390/v12090995 · Cited by 10
“All experimental protocols were approved by the IVDC, and the methods were carried out in accordance with the approved guidelines [21].”
MethodAlleman, M. M., Coulliette-Salmond, A. D., Pierre, W., Belgasmi, H., Sayyad, L., Wong, K., Gue, E., Barrais, R., Rey-Benito, G. J., Burns, C. C., et al. (2021) · Viruses · doi:10.3390/v13030505 · Cited by 14
“In April 2016, Haïti participated in the global switch, during which the use of trivalent OPV (tOPV, serotype 1-, 2-, and 3-containing) ceased and was replaced with bOPV1,3 [12,16].”
Chu, K., Han, W., Jiang, D., Jiang, Z., Zhu, T., Xu, W., Hu, Y., & Zeng, G. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1919091 · Cited by 9
Not your usual tRNA synthetase: hWARS serves as an enterovirus entry factor
Perlman, S. M., & Gallagher, T. (2018) · Journal of Clinical Investigation · doi:10.1172/jci124582 · Cited by 7
Australian National Enterovirus Reference Laboratory annual report, 2019
Hobday, L. K., Ibrahim, A., Kaye, M. E., Bruggink, L. D., Chanthalavanh, P., Garcia-Clapes, A., Roberts, J. A., & Thorley, B. R. (2020) · Communicable Diseases Intelligence · doi:10.33321/cdi.2020.44.94 · Cited by 6
“23 While the genetic sequence of some of these cVDPV2 outbreaks indicated a source preceding the switch to bivalent OPV in 2015, other instances were new emergences in countries adjoining those that had used monovalent OPV2 in response to their own more recent cVDPV2 outbreak.”
Multiscale model for forecasting Sabin 2 vaccine virus household and community transmission
Famulare, M., Wong, W., Haque, R., Platts-Mills, J. A., Saha, P., Aziz, A. B., Ahmed, T., Islam, M. O., Uddin, M., Bandyopadhyay, A. S., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009690 · Cited by 7
“The GPEI (Global Polio Eradication Initiative) is caught in a paradoxical situation because the current cVDPV2 containment strategy relies on immunization with monovalent Sabin 2 OPV (mOPV2) [6,7].”
BackgroundSelf-citationVirus Eradication and Synthetic Biology: Changes with SARS-CoV-2?
Tournier, J., & Kononchik, J. P. (2021) · Viruses · doi:10.3390/v13040569 · Cited by 6
“Vaccine-induced polio cases far exceed natural cases [3,18].”
BackgroundDürrheim, D. N. (2022) · International Health · doi:10.1093/inthealth/ihac068 · Cited by 6
Qualitative real-time RT-PCR assay for nOPV2 poliovirus detection
Dolgova, A. S., Kanaeva, O. I., Antonov, S. A., Shabalina, A. V., Klyuchnikova, E. O., Sbarzaglia, V. A., Gladkikh, A. S., Ivanova, O. E., Kozlovskaya, L. I., & Dedkov, V. G. (2024) · Journal of Virological Methods · doi:10.1016/j.jviromet.2024.114984 · Cited by 5
Li, J., Zhang, Z., Zhang, H., Li, M., Li, X., Lu, L., Huang, F., & Wu, J. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1778409 · Cited by 6
“To completely eliminate vaccine-derived polioviruses from the community, OPV withdrawal was planned in a phased manner.(17) To eradicate polio, WHO proposed the Polio Eradication and Endgame Strategic Plan 2013–2018, which recommended that ≥1 dose of inactivated poliovirus vaccine (IPV) should be added to the routine…”
BackgroundTournier, J. (2019) · médecine/sciences · doi:10.1051/medsci/2019005 · Cited by 5
Manukyan, H., Wahid, R., Ansari, A., Tritama, E., Macadam, A. J., Konz, J., Chumakov, K., & Laassri, M. (2022) · Vaccines · doi:10.3390/vaccines10091394 · Cited by 5
“To stop these outbreaks, monovalent OPV2 (mOPV2) was used, but it resulted in triggering new cVDPV2 outbreaks [8,9].”
BackgroundHan, Z., Xiao, J., Song, Y., Zhao, X., Sun, Q., Lu, H., Zhang, K., Li, J., Li, J., Si, F., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1019444 · Cited by 4
“All experimental protocols were approved by the IVDC and methods were carried out according to approved guidelines (Blake et al., 2018).”
MethodWong, W., Gauld, J., & Famulare, M. (2023) · Virus Evolution · doi:10.1093/ve/vead044 · Cited by 4
Xu, J., Liu, Y., Qiu, W., Li, W., Hu, X., Li, X., Fan, Q., Tang, W., Wang, Y., Wang, Q., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09389-8 · Cited by 3
GMO Regulatory Aspects of Novel Investigational Vaccine Candidates
Leunda, A., & Pauwels, K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85341 · Cited by 3
“Nevertheless, due to its induced superior mucosal immunity, monovalent OPV2 is still used in responses to outbreaks of cVDPV2, thereby challenging the feasibility of eradication of PV2 [25].”
BackgroundInfluentialA Novel Data Mining Approach for Detection of Polio Disease Using Spatio-Temporal Analysis
Khan, S. A., Azam, F., Anwar, M. W., Rasheed, Y., Saleem, M., & Ejaz, N. (2020) · International Conference on Computing and Artificial Intelligence (ICCAI) · doi:10.1145/3404555.3404591 · Cited by 3
“In [5] it is defined that; the poliovirus is being dying out from the world.”
BackgroundHan, Z., Song, Y., Xiao, J., Zhao, X., Lu, H., Zhang, K., Jia, S., Zhou, J., Li, J., Si, F., et al. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198501 · Cited by 3
Manukyan, H., Tritama, E., Wahid, R., Konopka‐Anstadt, J. L., Konz, J., Chumakov, K., & Laassri, M. (2023) · Vaccines · doi:10.3390/vaccines11111729 · Cited by 3
“To contain these outbreaks, monovalent OPV2 (mOPV2) was implemented, which resulted in seeding other new cVDPV2 outbreaks [12,13].”
BackgroundGemechu, D. S., & Gerema, U. (2020) · Case Reports in Infectious Diseases · doi:10.1155/2020/6917313 · Cited by 4
Pulmonale Hypertonie bei Linksherzerkrankungen
Opitz, C. F., Rieth, A. J., & Rosenkranz, S. (2017) · Der Klinikarzt · doi:10.1055/s-0043-116605 · Cited by 2
Mejía, L. R., Méndez, L. P., Rüttimann, R. W., Gast, C., & Bandyopadhyay, A. S. (2024) · Vaccines · doi:10.3390/vaccines12090953 · Cited by 2
“…this led to a high risk of cVDPV2 outbreaks in populations with low immunization levels because of the incompletely interrupted transmission of the Sabin strain poliovirus, which can lose its attenuations over time and revert to neurovirulent strains, giving rise to paralytic outbreaks [10–12].”
BackgroundSelf-citationAlland, S. E., Britton, P. N., Thorley, B. R., Hobday, L. K., Kelly, M., Fasugba, O., Wilson, M. G., Morris, A., & Dürrheim, D. N. (2025) · Australian and New Zealand Journal of Public Health · doi:10.1016/j.anzjph.2025.100281 · Cited by 2
Hipertensión pulmonar. Regreso al futuro
Rosenkranz, S., & Dumitrescu, D. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.04.004 · Cited by 2
Enteroviruses and rhinoviruses
Wang, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00062-9 · Cited by 4
Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination
Yu-ping, Z., Li, J., Huang, T., Zhi-fang, Y., Ting, Z., Yan-chun, C., Zhi-mei, Z., Fu, Y., Jun-hui, T., Yang, Q., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00642-w · Cited by 2
Estívariz, C. F., Burns, C. C., & Macklin, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00050-5 · Cited by 4
Pulmonary Hypertension–Back to the Future
Rosenkranz, S., & Dumitrescu, D. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.04.008 · Cited by 1
Lim, Y. H., Siti, M. S. G., Low, T. T., Kuntjoro, I., Yip, J., & Tay, E. L. W. (2020) · Singapore Medical Journal · doi:10.11622/smedj.2020026 · Cited by 1
Razafindratsimandresy, R., Joffret, M., Raharinantoanina, J., Polston, P. M., Andriamamonjy, S., Razanajatovo, I. M., Diop, O. M., Delpeyroux, F., Héraud, J., & Bessaud, M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28071 · Cited by 1
Self-citationSurekha, S., Kumar, A., Kasana, H., Meena, J., & Sayal, A. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00766 · Cited by 1
Selección de lo mejor del año 2016 en el tratamiento de la hipertensión pulmonar
Sánchez, M. Á. G., & Garrido-Lestache, E. B. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.11.025
Selection of the Best of 2016 in the Treatment of Pulmonary Hypertension
Sánchez, M. Á. G., & Garrido-Lestache, E. B. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.01.010
Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension
Subías, P. E., & Quezada-Loaiza, C. A. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.12.007
Hipertensión pulmonar (I). Hipertensión arterial pulmonar
Menéndez, S. C., Moreiras, J. M., Vega, P. Á., Calle, D. G., Manzanas, A. O., Subías, P. E., & Fernández, P. L. S. (2017) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2017.11.003
Elusive eradication: Challenges facing the worldwide eradication of polio
Mobley, D. J., & Hayney, M. S. (2018) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2018.10.004
Hipertensión pulmonar en el adulto
Orzaiz, B. A., Azofra, A. S., Alonso, T., & Pérez, F. J. G. (2018) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2018.11.012
Nigam, N., Tiwary, N. K., Agrawal, M., Verma, S., Gautam, M., Kumar, S., Verma, S. K., & Gupta, H. K. (2019) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2019/289
Pulmonale Hypertonie: Differenzialdiagnostik und therapeutische Konsequenzen
Rosenkranz, S. (2021) · Kardiologie up2date · doi:10.1055/a-1165-7581
Polio eradication: A perspective from the UK
Simons, H., & Patel, D. (2024) · New Microbes and New Infections · doi:10.1016/j.nmni.2024.101490
Singh, O., Manukyan, H., Tritama, E., Lee, S., Weir, J. P., & Laassri, M. (2025) · Vaccines · doi:10.3390/vaccines13010075
“To control these outbreaks, monovalent OPV2, derived solely from the Sabin 2 virus, was instituted, leading to further cVDPV2 outbreaks [14,15].”
Sun, Y., Keskinocak, P., Peak, C. M., & Steimle, L. N. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128707
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741228
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741222
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741219
Epidemiology and vaccination strategies against type-2 vaccine -derived poliovirus
Macklin, G. (2023) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.04670892
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741216
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741225
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741231
Tian, X., Zhenzhi, H., He, Y., Sun, Q., Wang, W., Xu, W., Li, H., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14741234
Metadata
- Authors
- Blake, I. M., Pons-Salort, M., Molodecky, N. A., Diop, O. M., Chenoweth, P., Bandyopadhyay, A. S., Zaffran, M., Sutter, R. W., & Grassly, N. C.
- Affiliations
- Gates Foundation (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-30
- Volume
- 379
- Issue
- 9
- Pages
- 834-845
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5985919
- OpenAlex
- W2889458573
- Cited by
- 79
- References
- 24
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 17 · 2020: 17 · 2019: 4 · 2018: 6
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Bill and Melinda Gates Foundation (OPP1099374)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- poliovirus type 2, vaccine-derived poliovirus, polio eradication, acute flaccid paralysis surveillance, wastewater surveillance, routine immunization coverage, poliovirus outbreak
- MeSH terms
- Adolescent, Africa, Asia, Child, Child, Preschool, Disease Outbreaks, Feces, Female, Humans, Infant, Infant, Newborn, Male, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Population Surveillance, Sewage, Logistic Models, Poliovirus, Disease Eradication, Serogroup
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



